Skip to main content
Erschienen in: Medical Oncology 3/2015

01.03.2015 | Original Paper

VGLL4 inhibits EMT in part through suppressing Wnt/β-catenin signaling pathway in gastric cancer

verfasst von: Hui Li, Ziwei Wang, Wei Zhang, Kun Qian, Gang Liao, Wei Xu, Shouru Zhang

Erschienen in: Medical Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

VGLL4 is a member of the Vestigial-like proteins that functions as a tumor suppressor, which directly competes with YAP for binding TEADs in several cancer types. Recently, an increasing number of studies have reported that VGLL4 acts as a crucial role in regulating cell mobility, migration, and invasion. However, little is known about the signaling mechanisms in regulating epithelial–mesenchymal transition (EMT) of gastric cancer. In our study, we confirmed that the expression level of VGLL4 was down-regulated in gastric cancer tissues, and reduced VGLL4 expression levels inhibited apoptosis and promoted proliferation, migration, and invasion. Additionally, we found a phenomenon that VGLL4 was associated with the change in nuclear location of β-catenin, which suggested that β-catenin was a significant downstream factor of VGLL4. These results suggest that VGLL4 suppressed EMT in part via negative regulation of Wnt/β-catenin signaling pathway. Taken together, our study demonstrated that VGLL4 is important in the process of suppressing tumor progression of gastric cancer and provided a potential therapeutic strategy for gastric cancer.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRefPubMed
3.
Zurück zum Zitat Fuxe J, Vincent T, de Herreros AG. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle. 2010;9:2363–74.CrossRefPubMed Fuxe J, Vincent T, de Herreros AG. Transcriptional crosstalk between TGF-beta and stem cell pathways in tumor cell invasion: role of EMT promoting Smad complexes. Cell Cycle. 2010;9:2363–74.CrossRefPubMed
4.
Zurück zum Zitat Bates RC, Mercurio AM. The epithelial–mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther. 2005;4:365–70.CrossRefPubMed Bates RC, Mercurio AM. The epithelial–mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther. 2005;4:365–70.CrossRefPubMed
5.
Zurück zum Zitat Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.CrossRefPubMed Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.CrossRefPubMed
6.
Zurück zum Zitat Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009;139:871–90.CrossRefPubMed Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009;139:871–90.CrossRefPubMed
7.
Zurück zum Zitat Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.CrossRefPubMed Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.CrossRefPubMed
8.
Zurück zum Zitat Yang J, Weinberg RA. Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14:818–29.CrossRefPubMed Yang J, Weinberg RA. Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14:818–29.CrossRefPubMed
9.
11.
Zurück zum Zitat Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265–73.CrossRefPubMed Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265–73.CrossRefPubMed
12.
Zurück zum Zitat Bardeesy N, Cheng KH, Berger JH, Chu GC, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006;20(22):3130–46.PubMedCentralCrossRefPubMed Bardeesy N, Cheng KH, Berger JH, Chu GC, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006;20(22):3130–46.PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Wang Z, Li Y, Kong D, Banerjee S, et al. Acquisition of epithelial–mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69(6):2400–7.PubMedCentralCrossRefPubMed Wang Z, Li Y, Kong D, Banerjee S, et al. Acquisition of epithelial–mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69(6):2400–7.PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Fu Y, Zheng S, An N, et al. β-catenin as a potential key target for tumor suppression. Int J Cancer. 2011;129(7):1541–51.CrossRefPubMed Fu Y, Zheng S, An N, et al. β-catenin as a potential key target for tumor suppression. Int J Cancer. 2011;129(7):1541–51.CrossRefPubMed
16.
Zurück zum Zitat Anson M, Crain-Denoyelle AM, Baud V, et al. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest. 2012;122(2):586–99.PubMedCentralCrossRefPubMed Anson M, Crain-Denoyelle AM, Baud V, et al. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest. 2012;122(2):586–99.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 1997;11(24):3286–305.CrossRefPubMed Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 1997;11(24):3286–305.CrossRefPubMed
18.
19.
Zurück zum Zitat Chen HH, Mullett SJ, Stewart AF. Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha1- adrenergic activation of gene expression in cardiac myocytes. J Biol Chem. 2004;279(29):30800–6.CrossRefPubMed Chen HH, Mullett SJ, Stewart AF. Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha1- adrenergic activation of gene expression in cardiac myocytes. J Biol Chem. 2004;279(29):30800–6.CrossRefPubMed
20.
Zurück zum Zitat Mielcarek M, Gunther S, Kruger M, et al. VITO-1, a novel vestigial related protein is predominantly expressed in the skeletal muscle lineage. Gene Expr Patterns. 2002;2(3–4):305–10.CrossRefPubMed Mielcarek M, Gunther S, Kruger M, et al. VITO-1, a novel vestigial related protein is predominantly expressed in the skeletal muscle lineage. Gene Expr Patterns. 2002;2(3–4):305–10.CrossRefPubMed
21.
Zurück zum Zitat Mielcarek M, Piotrowska I, Schneider A, et al. VITO-2, a new SID domain protein, is expressed in the myogenic lineage during early mouse embryonic development. Gene Expr Patterns. 2009;9(3):129–37.CrossRefPubMed Mielcarek M, Piotrowska I, Schneider A, et al. VITO-2, a new SID domain protein, is expressed in the myogenic lineage during early mouse embryonic development. Gene Expr Patterns. 2009;9(3):129–37.CrossRefPubMed
22.
Zurück zum Zitat Pobbati AV, Hong W. Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther. 2012;14(5):390–8.CrossRef Pobbati AV, Hong W. Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther. 2012;14(5):390–8.CrossRef
23.
Zurück zum Zitat Pobbati AV, Chan SW, Lee I, et al. Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD complexes. Structure. 2012;20(7):1135–40.CrossRefPubMed Pobbati AV, Chan SW, Lee I, et al. Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD complexes. Structure. 2012;20(7):1135–40.CrossRefPubMed
24.
Zurück zum Zitat Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9(2):121–32.CrossRefPubMed Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9(2):121–32.CrossRefPubMed
25.
Zurück zum Zitat Helias-Rodzewicz Z, Perot G, Chibon F, et al. YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes Chromosom Cancer. 2012;49(12):1161–71.CrossRef Helias-Rodzewicz Z, Perot G, Chibon F, et al. YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes Chromosom Cancer. 2012;49(12):1161–71.CrossRef
26.
Zurück zum Zitat Mann KM, Ward JM, Yew CC, et al. Sleeping beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci USA. 2012;109(16):5934–41.PubMedCentralCrossRefPubMed Mann KM, Ward JM, Yew CC, et al. Sleeping beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci USA. 2012;109(16):5934–41.PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Jin HS, Park HS, Shin JH, et al. A novel inhibitor of apoptosis protein (IAP)-interacting protein, Vestigial-like (Vgl)-4, counteracts apoptosis-inhibitory function of IAPs by nuclear sequestration. Biochem Biophys Res Commun. 2012;412(3):454–9.CrossRef Jin HS, Park HS, Shin JH, et al. A novel inhibitor of apoptosis protein (IAP)-interacting protein, Vestigial-like (Vgl)-4, counteracts apoptosis-inhibitory function of IAPs by nuclear sequestration. Biochem Biophys Res Commun. 2012;412(3):454–9.CrossRef
28.
Zurück zum Zitat Jiao S, Wang H, Shi Z, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014;25(2):166–80.CrossRefPubMed Jiao S, Wang H, Shi Z, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014;25(2):166–80.CrossRefPubMed
29.
Zurück zum Zitat Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in Hepatocellular carcinoma. Cancer. 2009;115:4576–85.PubMedCentralCrossRefPubMed Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in Hepatocellular carcinoma. Cancer. 2009;115:4576–85.PubMedCentralCrossRefPubMed
30.
Zurück zum Zitat Xu W, Wang Z, Zhang W et al. Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway. Cancer Lett. 2015;356(2 Pt B):613–27.CrossRefPubMed Xu W, Wang Z, Zhang W et al. Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway. Cancer Lett. 2015;356(2 Pt B):613–27.CrossRefPubMed
31.
Zurück zum Zitat Zha L, Zhang J, Tang W, et al. HMGA2 elicits EMT by activating the Wnt/b-catenin pathway in gastric cancer. Dig Dis Sci. 2013;58:724–33.CrossRefPubMed Zha L, Zhang J, Tang W, et al. HMGA2 elicits EMT by activating the Wnt/b-catenin pathway in gastric cancer. Dig Dis Sci. 2013;58:724–33.CrossRefPubMed
32.
Zurück zum Zitat Zhang W, Gao Y, Li P, et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 2014;24(3):331–43.PubMedCentralCrossRefPubMed Zhang W, Gao Y, Li P, et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 2014;24(3):331–43.PubMedCentralCrossRefPubMed
Metadaten
Titel
VGLL4 inhibits EMT in part through suppressing Wnt/β-catenin signaling pathway in gastric cancer
verfasst von
Hui Li
Ziwei Wang
Wei Zhang
Kun Qian
Gang Liao
Wei Xu
Shouru Zhang
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-015-0539-5

Weitere Artikel der Ausgabe 3/2015

Medical Oncology 3/2015 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.